Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.
about
Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complexThe evolution of poxvirus vaccinesSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesComparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal deliveryNonreplicating vectors in HIV vaccines.Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.A stimulating way to improve T cell responses to poxvirus-vectored vaccinesEffect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.Intradermal delivery of vaccines: potential benefits and current challenges.Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Smallpox vaccines: targets of protective immunity.A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responsesVaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsA quantitative comet infection assay for influenza virus.Selection of recombinant MVA by rescue of the essential D4R gene.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored VaccinesImpact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesSafety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.Intradermal vaccination for infants and children.Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.Current opportunities and challenges in intradermal vaccination.MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.Enhancing health care worker ability to detect and care for patients with monkeypox in the Democratic Republic of the Congo.Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response.First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine.
P2860
Q21089588-9D99CF36-2853-4071-BFAA-7DB38FEC058FQ26995905-FE4F04AB-3FBB-4245-8476-12E26068C72EQ27325586-BD65E2C5-23F4-4E69-B2DC-ED449DE310EBQ33603206-58595707-06B1-40C8-A3E3-44ED3D76C5CEQ33693891-DEB1E483-1C59-4163-944E-CE7F3961D326Q34023588-CA29BACC-30BD-4673-892D-7B48C21E475AQ34182371-8C894B5C-9337-4840-B492-507F8CCAF898Q34420319-F7D8B18A-B304-4650-9117-336076B1544CQ34429078-94925190-BDC8-433D-9CD0-DFA4D730CD74Q34502997-6E647F42-2DD2-4B09-8A95-18EBB1DC4E0CQ34601669-5C30C30C-1F3D-4E71-80A4-04F4B70D089FQ34729962-A98A30AB-D603-4AD2-9130-762ECCC1B976Q34780607-7537F607-32A5-4D59-BEEC-03A69099AE51Q34952043-A423BD8E-CE55-472A-8AA5-B1F6C6ED6135Q35571248-35F80E70-0F0F-4EE8-A7DD-3098A0E57D57Q35634159-227A4420-A006-470E-8030-F2E42E6FD91AQ35667169-59F71113-2BB7-451D-B404-01A0ECBB70E3Q35800430-44192454-F980-4F79-8356-FFA62092F701Q35826728-9F3486C8-3CCD-439A-AA25-4E9DBB84E062Q35928588-97DC161B-3435-4F55-8D2D-28D5F38B29E7Q36593175-2035D108-5403-40EF-98B2-6D7EDB44C47BQ36846282-6B98ADB4-822A-4822-A79B-78C8D7D56EC8Q37264939-D54A8EF6-586E-4F1C-B620-60A6832D8E27Q37791160-7AC67A62-6170-44AE-A3C0-455D76DBD7E8Q38604987-6D774475-CFC1-4BE9-ABA0-21D2FAA77909Q40497816-885420B5-AD11-4F62-BA10-CD158FEFC5CEQ46579432-200009BF-1AA8-47B4-87A6-40508EF6ACE4Q49958499-759D862C-9169-4CA3-BC32-D52A1C3EB84EQ52580309-DC3930EA-671D-4955-8451-B7E468E02EF3Q55397871-5A2FFB08-371E-4528-B299-90836CBAA5E1
P2860
Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Safety and immunogenicity of m ...... e and route of administration.
@ast
Safety and immunogenicity of m ...... e and route of administration.
@en
Safety and immunogenicity of modified vaccinia Ankara
@nl
type
label
Safety and immunogenicity of m ...... e and route of administration.
@ast
Safety and immunogenicity of m ...... e and route of administration.
@en
Safety and immunogenicity of modified vaccinia Ankara
@nl
prefLabel
Safety and immunogenicity of m ...... e and route of administration.
@ast
Safety and immunogenicity of m ...... e and route of administration.
@en
Safety and immunogenicity of modified vaccinia Ankara
@nl
P2093
P2860
P356
P1476
Safety and immunogenicity of m ...... se and route of administration
@en
P2093
Ayush Giri
Colleen Devoy
Haesook T Kim
Jane A Kleinjan
Kristen E Stevenson
Lauren E Grandpre
Lizanne C Noble
Marissa B Wilck
Michael S Seaman
Raphael Dolin
P2860
P304
P356
10.1086/651561
P407
P577
2010-05-01T00:00:00Z